Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scorman1	11/25/2024 9:49:45 AM
	Read Replies (1) of 63304

On SAVA, here is where I eat crow....doc was right this was a hard nut to crack. Screwed by over achieving placebo, but it has happened before. I am NOT be optimistic, but I understand why they cancelled the second phase 3 immediately. Many of the second trial completed 18 months and I'll presume that all completed 12 months same as in the first trial endpoint Split 1:1:1 50mg,100,mg, placebo now presents data that can be accumulated and added to first data set. Statistics is all about sample size and running an SAS analysis will pick up any correlation besides "there was a positive trend". It still miffs me that here were obvious super responders and I only hope that a compassionate use will be afforded to those who ask, since the pills are not being dispensed anyway. Just like with AIDS, patients don't get better on their own. We need detailed numbers not TLR. Cash value of slightly less than $4 is not a consolation prize, and hopefully they don't sell the company at a fire sale.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next